questionsmedicales.fr
Thérapeutique
Traitement médicamenteux
Traitements médicamenteux de la COVID-19
Traitements médicamenteux de la COVID-19 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Prévention
5
Mesures de prévention
COVID-19
Anticorps monoclonaux
Prévention
Masques
Transmission virale
Traitements
5
Effets secondaires
Traitements médicamenteux
Facteurs de risque
5
Facteurs de risque
COVID-19
Immunodépression
COVID-19
Antécédents médicaux
COVID-19
Origine ethnique
COVID-19
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Traitements médicamenteux de la COVID-19 : Questions médicales les plus fréquentes",
"headline": "Traitements médicamenteux de la COVID-19 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Traitements médicamenteux de la COVID-19 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-17",
"dateModified": "2025-04-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Traitements médicamenteux de la COVID-19"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Traitement médicamenteux",
"url": "https://questionsmedicales.fr/mesh/D004358",
"about": {
"@type": "MedicalCondition",
"name": "Traitement médicamenteux",
"code": {
"@type": "MedicalCode",
"code": "D004358",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.319"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Traitements médicamenteux de la COVID-19",
"alternateName": "COVID-19 Drug Treatment",
"code": {
"@type": "MedicalCode",
"code": "D000093485",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Didier Raoult",
"url": "https://questionsmedicales.fr/author/Didier%20Raoult",
"affiliation": {
"@type": "Organization",
"name": "Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France; IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France."
}
},
{
"@type": "Person",
"name": "Francesco Potì",
"url": "https://questionsmedicales.fr/author/Francesco%20Pot%C3%AC",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine and Surgery - Unit of Neurosciences, University of Parma, Parma, Italy. francesco.poti@unipr.it."
}
},
{
"@type": "Person",
"name": "Taher Entezari-Maleki",
"url": "https://questionsmedicales.fr/author/Taher%20Entezari-Maleki",
"affiliation": {
"@type": "Organization",
"name": "Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. tentezari@gmail.com."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "David Brandariz-Nuñez",
"url": "https://questionsmedicales.fr/author/David%20Brandariz-Nu%C3%B1ez",
"affiliation": {
"@type": "Organization",
"name": "Servicio de Farmacia, Hospital Quironsalud, Barcelona, España. Electronic address: vrandariz@gmail.com."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Interleukin-6",
"datePublished": "2023-04-25",
"url": "https://questionsmedicales.fr/article/37097384",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10238-023-01081-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Race, Interleukin-6,",
"datePublished": "2022-09-14",
"url": "https://questionsmedicales.fr/article/36102277",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1161/JAHA.122.025627"
}
},
{
"@type": "ScholarlyArticle",
"name": "Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.",
"datePublished": "2022-08-11",
"url": "https://questionsmedicales.fr/article/35953263",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/ard-2022-222784"
}
},
{
"@type": "ScholarlyArticle",
"name": "A call for clinical trials in glioblastoma multiforme for interleukin 4, interleukin 6, interleukin 13 and CD40.",
"datePublished": "2024-09-07",
"url": "https://questionsmedicales.fr/article/39242402",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10143-024-02823-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "No Association of Polymorphisms in the Genes Encoding Interleukin-6 and Interleukin-6 Receptor Subunit Alpha with the Risk of Keloids in Polish Patients.",
"datePublished": "2024-05-13",
"url": "https://questionsmedicales.fr/article/38791322",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms25105284"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Thérapeutique",
"item": "https://questionsmedicales.fr/mesh/D013812"
},
{
"@type": "ListItem",
"position": 3,
"name": "Traitement médicamenteux",
"item": "https://questionsmedicales.fr/mesh/D004358"
},
{
"@type": "ListItem",
"position": 4,
"name": "Traitements médicamenteux de la COVID-19",
"item": "https://questionsmedicales.fr/mesh/D000093485"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Traitements médicamenteux de la COVID-19 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Traitements médicamenteux de la COVID-19",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Traitements médicamenteux de la COVID-19",
"description": "Les vaccins préviennent-ils la COVID-19 ?\nQuelles mesures de prévention sont recommandées ?\nLes traitements préventifs existent-ils ?\nLes masques chirurgicaux sont-ils efficaces ?\nLa vaccination est-elle obligatoire ?",
"url": "https://questionsmedicales.fr/mesh/D000093485?mesh_terms=Interleukin-6#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Traitements médicamenteux de la COVID-19",
"description": "Quels médicaments sont utilisés pour traiter la COVID-19 ?\nComment fonctionne le remdesivir ?\nLa dexaméthasone est-elle efficace pour tous les patients ?\nQuels sont les effets secondaires des traitements ?\nLes antibiotiques sont-ils utiles contre la COVID-19 ?",
"url": "https://questionsmedicales.fr/mesh/D000093485?mesh_terms=Interleukin-6#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Traitements médicamenteux de la COVID-19",
"description": "Quelles sont les complications possibles de la COVID-19 ?\nComment la COVID-19 affecte-t-elle le cœur ?\nLes séquelles de la COVID-19 sont-elles fréquentes ?\nLa COVID-19 peut-elle affecter le système nerveux ?\nQuels sont les risques de thrombose ?",
"url": "https://questionsmedicales.fr/mesh/D000093485?mesh_terms=Interleukin-6#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Traitements médicamenteux de la COVID-19",
"description": "Quels sont les principaux facteurs de risque ?\nLes personnes immunodéprimées sont-elles plus à risque ?\nLe sexe influence-t-il la gravité de la maladie ?\nLes antécédents médicaux jouent-ils un rôle ?\nL'origine ethnique influence-t-elle le risque ?",
"url": "https://questionsmedicales.fr/mesh/D000093485?mesh_terms=Interleukin-6#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Les vaccins préviennent-ils la COVID-19 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccins réduisent le risque d'infection et de formes graves de la maladie."
}
},
{
"@type": "Question",
"name": "Quelles mesures de prévention sont recommandées ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le port du masque, la distanciation sociale et le lavage des mains sont essentiels."
}
},
{
"@type": "Question",
"name": "Les traitements préventifs existent-ils ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements comme les anticorps monoclonaux peuvent être utilisés en prévention chez certains patients."
}
},
{
"@type": "Question",
"name": "Les masques chirurgicaux sont-ils efficaces ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils réduisent la transmission du virus en filtrant les gouttelettes respiratoires."
}
},
{
"@type": "Question",
"name": "La vaccination est-elle obligatoire ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend des réglementations locales, mais elle est fortement recommandée."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter la COVID-19 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antiviraux comme le remdesivir et des corticostéroïdes comme la dexaméthasone sont utilisés."
}
},
{
"@type": "Question",
"name": "Comment fonctionne le remdesivir ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le remdesivir inhibe la réplication du virus en bloquant l'ARN polymérase virale."
}
},
{
"@type": "Question",
"name": "La dexaméthasone est-elle efficace pour tous les patients ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est efficace principalement chez les patients gravement malades nécessitant de l'oxygène."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des infections, des troubles gastro-intestinaux et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les antibiotiques sont-ils utiles contre la COVID-19 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les antibiotiques ne traitent pas les infections virales comme la COVID-19."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la COVID-19 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la pneumonie, le syndrome de détresse respiratoire et des problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Comment la COVID-19 affecte-t-elle le cœur ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut provoquer des myocardites et des arythmies, augmentant le risque de complications cardiaques."
}
},
{
"@type": "Question",
"name": "Les séquelles de la COVID-19 sont-elles fréquentes ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreux patients présentent des symptômes persistants, appelés COVID long."
}
},
{
"@type": "Question",
"name": "La COVID-19 peut-elle affecter le système nerveux ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes neurologiques comme des maux de tête et des troubles de l'odorat peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de thrombose ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "La COVID-19 augmente le risque de thrombose veineuse et d'embolie pulmonaire."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge avancé, les maladies chroniques et l'obésité."
}
},
{
"@type": "Question",
"name": "Les personnes immunodéprimées sont-elles plus à risque ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles présentent un risque accru de formes graves de la COVID-19."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il la gravité de la maladie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études montrent que les hommes peuvent avoir des formes plus graves que les femmes."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies respiratoires ou cardiovasculaires augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'origine ethnique influence-t-elle le risque ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que certaines ethnies peuvent être plus touchées par la COVID-19."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 11/04/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France; IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine and Surgery - Unit of Neurosciences, University of Parma, Parma, Italy. francesco.poti@unipr.it.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. tentezari@gmail.com.
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. tentezari@gmail.com.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Servicio de Farmacia, Hospital Quironsalud, Barcelona, España. Electronic address: vrandariz@gmail.com.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Servicio de Farmacia, Hospital CIMA, Barcelona, España.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Centre for Safe Medication Practice and Research Department of Pharmacology and Pharmacy LKS Faculty of Medicine University of Hong Kong Hong Kong Special Administrative Region, 1/F, Jockey Club Building for Interdisciplinary Research, 5 Sassoon Road Pokfulam Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Department of Computer Science Faculty of Engineering University of Hong Kong Hong Kong Special Administrative Region, CB303, Chow Yei Ching Building Pokfula Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Centre for Safe Medication Practice and Research Department of Pharmacology and Pharmacy LKS Faculty of Medicine University of Hong Kong Hong Kong Special Administrative Region, 1/F, Jockey Club Building for Interdisciplinary Research, 5 Sassoon Road Pokfulam Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Department of Computer Science Faculty of Engineering University of Hong Kong Hong Kong Special Administrative Region, CB303, Chow Yei Ching Building Pokfula Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Department of Computer Science Faculty of Engineering University of Hong Kong Hong Kong Special Administrative Region, CB303, Chow Yei Ching Building Pokfula Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
School of Data Science City University of Hong Kong Hong Kong Special Administrative Region, 83 Tat Chee Avenue Kowloon Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Department of Computer Science and Engineering Southern University of Science and Technology 1088 Xueyuan Avenue, Nanshan District Shenzhen Guangdong 518055 China.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Division of Epidemiology and Biostatistics School of Public Health University of Hong Kong Hong Kong Special Administrative Region, 21 Sassoon Road Pokfulam Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Division of Infectious Diseases Department of Medicine LKS Faculty of Medicine University of Hong Kong Hong Kong Special Administrative Region, 102 Pokfulam Road Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
2 publications dans cette catégorie
Affiliations :
Division of Cardiology Department of Medicine University of Hong Kong Hong Kong Special Administrative Region, 102 Pokfulam Road Hong Kong SAR China.
Publications dans "Traitements médicamenteux de la COVID-19" :
In a convenience sample of 93 patients treated with monoclonal antibodies (moAbs) against SARS-CoV-2, the interleukin-6...
Background Differences in death rate and cardiovascular disease (CVD) between Black and White patients with chronic kidney disease is attributed to sociocultural factors, comorbidities, genetics, and ...
Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific recept...
A systematic literature research was performed that focused on IL-6-pathway inhibitors in inflammatory diseases. Evidence was put in context by a large group of international experts and patients in a...
The consensus process covered relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyar...
The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and p...
Glioblastoma multiforme (GBM) is one of the most aggressive and deadly forms of brain cancer, which has a very complex tumor microenvironment (TME) promoting tumor growth, immune evasion, and resistan...
A keloid is a benign fibroproliferative hypertrophy of scar tissue that extends outside the original wound and invades adjacent healthy skin. Keloid formation is thought to be a complex process includ...
Obsessive-compulsive disorder (OCD) is a highly prevalent neuropsychiatric disorder. Recently, there has been a growing interest in investigating the association between pro-inflammatory cytokines and...
This study recruited 58 OCD patients and 30 age-sex-matched healthy controls (HCs). A qualified psychiatrist diagnosed OCD patients and assessed HCs based on the Diagnostic and Statistical Manual for ...
The results showed that serum IL-1β levels were significantly elevated in OCD patients compared to HCs (23.68±1.65 pg/ml vs. 15.75±1.02 pg/ml; p = 0.002). Similarly, OCD patients exhibited significant...
These results suggest that serum IL-1β and IL-6 levels may be associated with the pathophysiology of OCD. Also, these cytokines levels in blood samples can serve as early risk assessment tools for the...
The differentiation and function of osteocytes are controlled by surrounding cells and mechanical stress; however, the detailed mechanisms are unknown. Recent findings suggest that IL-33 is highly exp...
Alzheimer's disease (AD), characterized by the abnormal accumulation of...
Autoinflammatory diseases are characterized by abnormalities that prevent innate immune cells from producing autoantibodies. While interleukin (IL)-6 is not directly associated with inflammasomes, lik...
To assess the prognostic value of serum interleukin-6 (IL-6), nuclear factor-...
From May 2019 to March 2020, 104 patients with diabetic nephropathy treated in our institution assessed for eligibility were recruited and assigned at a ratio of 1 : 1 to either the observation group ...
The eligible patients with UAER of 30 mg-300 mg/24 h were associated with significantly higher levels of IL-6, MCP-1, NF-...
Serum IL-6, NF-...